Tuesday's Health Winners & Losers

Updated from 3:05 p.m. EDT

Health-related stock indices were mixed after the long holiday weekend Tuesday, as some stocks climbed with no announcements and others lagged on neutral-to-positive news.

Qiagen(QGEN Quote) announced on Tuesday that it signed a new licensing agreement with Germany's Epigenomics, expanding on one from 2005. The new agreement gives the Netherlands-based company the exclusive worldwide rights to Epigenomics' sample technologies for use in applied testing and in in-vitro molecular diagnostics.

Epigenomics receives an upfront fee and further milestone payments and royalties, though precise financial terms weren't disclosed. A nonexclusive back-license also gives Epigenomics the rights to use the technologies in developmental projects and to commercialize in-vitro molecular diagnostics. Shares of Qiagen were up 28 cents, or 1.7%, to $17.21.

Among those climbing on no apparent news were Affymetrix(AFFX Quote), which rose 77 cents, or 3%, to $26.26, and InterMune(ITMN Quote), which increased 66 cents, or 2.6%, to $26.05. Both stocks are part of the Amex Bioptechnology Index, which was up 6.39, or 0.8%, to 818.62.

Micrus Endovascular(MEND Quote) said Tuesday that it received 510(k) clearance from the Food and Drug Administration for its Enzo steerable microcatheter. However, its stock was down 31 cents, or 1.5%, to $21.04.